🟢 Bayer is trading 4.19% up on October 30, 2026, after Monsanto wins Roundup cancer trial

Bayer is trading at €47.96, up 4.19%, with the move likely supported by a jury verdict for Bayer-owned Monsanto in a Roundup cancer trial.

• The St. Louis verdict was the first such trial after a favorable U.S. Supreme Court ruling; Reuters reported its relevance to Bayer’s broader litigation exposure.
• Bayer’s Q3 results are scheduled for November 3 and do not explain the move. No trading-volume information was available in the cited reports.